The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 3 A MGS values throughout the study duration. B Comparison between MGS values among study group (n = 30) throughout study duration

From: The use of dexamethasone therapy for conservative management of chronic subdural hematomas: a question about efficacy and safety

MGS	Day 1 (n = 30) (%)	Day 14 (n = 30) (%)	1 month (n = 30) (%)	3 months^# (n = 29) (%)	6 months^# (n = 29) (%)
0	0 (0.0)	3 (10.0)	10 (33.3)	17 (58.6)	24 (82.8)
1	11 (36.7)	22 (73.3)	18 (60.0)	12 (41.4)	5 (17.2)
2	19 (63.3)	5 (16.7)	1 (3.3)	0 (0.0)	0 (0.0)
3	0 (0.0)	0 (0.0)	1 (3.3)	0 (0.0)	0 (0.0)

Comparison	Chi-square test	p-value
Day 1 vs. Day 14	14.833	< 0.001**
Day 1 vs. 1 M	28.890	< 0.001**
Day 1 vs. 3 M	36.037	< 0.001**
Day 1 vs. 6 M	45.246	< 0.001**
Day 14 vs. 1 M	7.836	0.049*
Day 14 vs. 3 M	17.729	< 0.001**
Day 14 vs. 6 M	32.029	< 0.001**
1 M vs. 3 M	4.999	0.172
1 M vs. 6 M	15.100	0.002*
3 M vs. 6 M	2.996	0.084

Using: Chi-square test
GCS Markwalder Grading Scale (), n number of patients, M months after protocol initiation)
p-value > 0.05 is insignificant; *p-value < 0.05 is significant; **p-value < 0.001 is highly significant
^#one case of deceased

Back to article page